

Mojca Maticic

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9221538/mojca-maticic-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

34
papers

785
citations

14
h-index

28
g-index

38
ext. papers

997
ext. citations

5.3
avg, IF

4.49
L-index

#	Paper	IF	Citations
34	Hepatitis B Elimination in Children of Slovenian Origin Born in Slovenia After the Introduction of Preventive Strategies: the Results of a National Study.. <i>Zdravstveno Varstvo</i> , 2022 , 61, 109-114	1.3	
33	Elimination of hepatitis C in Europe: can WHO targets be achieved?. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 818-823	9.5	18
32	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. <i>JHEP Reports</i> , 2020 , 2, 100113	10.3	280
31	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020 , 40, 260-270	7.9	14
30	The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries. <i>Harm Reduction Journal</i> , 2020 , 17, 89	4.6	4
29	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. <i>PLoS ONE</i> , 2020 , 15, e0235715	3.7	7
28	Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. <i>JHEP Reports</i> , 2020 , 2, 100169	10.3	68
27	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data 2020 , 15, e0235715		
26	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data 2020 , 15, e0235715		
25	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data 2020 , 15, e0235715		
24	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data 2020 , 15, e0235715		
23	Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries. <i>Harm Reduction Journal</i> , 2019 , 16, 32	4.6	10
22	We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. <i>Journal of Internal Medicine</i> , 2019 , 286, 503-525	10.8	39
21	State of viral hepatitis care in 16 countries of Central and Eastern European Region. <i>Central European Journal of Public Health</i> , 2019 , 27, 212-216	1.2	1
20	Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework. <i>Liver International</i> , 2019 , 39, 20-30	7.9	49
19	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. <i>Journal of Hepatology</i> , 2018 , 68, 402-411	13.4	77
18	Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017. <i>Journal of the International AIDS Society</i> , 2018 , 21 Suppl 2, e25052	5.4	13

17	Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. <i>Antiviral Research</i> , 2018 , 150, 9-14	10.8	14
16	The benefits of hepatitis C virus cure: Every rose has thorns. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 320-328	3.4	11
15	Distribution of hepatitis B virus genotypes in Europe and clinical implications: a review. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2018 , 27, 141-146	0.7	1
14	Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses. <i>International Journal of Drug Policy</i> , 2017 , 47, 47-50	5.5	17
13	The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs. <i>Hepatology, Medicine and Policy</i> , 2016 , 1, 14		5
12	Confirmed inguinal lymphogranuloma venereum genovar L2c in a man who had sex with men, Slovenia, 2015. <i>Eurosurveillance</i> , 2016 , 21, 2-5	19.8	8
11	Central nervous system granulomatous phlebitis with limited extracranial involvement of the heart and lungs: An autopsy case. <i>Neuropathology</i> , 2016 , 36, 88-92	2	3
10	Trichomoniasis: a brief review of diagnostic methods and our experience with real-time PCR for detecting infection. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2015 , 24, 7-10	0.7	5
9	High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against <i>Neisseria gonorrhoeae</i> isolates with various high-level antimicrobial resistance and multidrug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1866-72	5.1	15
8	Phenotypic and molecular characterization of <i>Neisseria gonorrhoeae</i> isolates from Slovenia, 2006-12: rise and fall of the multidrug-resistant NG-MAST genogroup 1407 clone?. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1517-25	5.1	32
7	Prevalence, genotype distribution, and risk factors for hepatitis C infection among HIV-infected individuals in Slovenia: a 1986-2013 update. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2014 , 23, 25-6	0.7	5
6	P7: Combination of fluvastatin and standard of care treatment reduces viral relapse in chronic hepatitis C genotype 1 but not genotype 3 patients. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 19-19	3.4	
5	P3.270 Antimicrobial Susceptibility and Molecular Characterization of <i>Neisseria Gonorrhoeae</i> Strains from Slovenia 2008-2012. <i>Sexually Transmitted Infections</i> , 2013 , 89, A233.1-A233	2.8	
4	Lichen planus and other cutaneous manifestations in chronic hepatitis C: pre- and post-interferon-based treatment prevalence vary in a cohort of patients from low hepatitis C virus endemic area. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2008 , 22, 779-88	4.6	26
3	The IgG antibody profile to various antigen regions of hepatitis C virus differs in oral fluid and serum of patients with chronic hepatitis C. <i>Oral Microbiology and Immunology</i> , 2003 , 18, 176-82		4
2	Proviral HIV-1 DNA in gingival crevicular fluid of HIV-1-infected patients in various stages of HIV disease. <i>Journal of Dental Research</i> , 2000 , 79, 1496-501	8.1	39
1	Tick-borne encephalitis: possibly a fatal disease in its acute stage. PCR amplification of TBE RNA from postmortem brain tissue. <i>Infection</i> , 1997 , 25, 41-3	5.8	20